| Literature DB >> 32756064 |
Giovanna Mantovani1, Murat Bastepe2, David Monk3, Luisa de Sanctis4, Susanne Thiele5, S Faisal Ahmed6, Roberto Bufo7, Timothée Choplin8, Gianpaolo De Filippo9, Guillemette Devernois8, Thomas Eggermann10, Francesca M Elli1, Aurora Garcia Ramirez11, Emily L Germain-Lee12,13, Lionel Groussin14,15, Neveen A T Hamdy16, Patrick Hanna17, Olaf Hiort5, Harald Jüppner2, Peter Kamenický17,18,19, Nina Knight20, Elvire Le Norcy15,21, Beatriz Lecumberri22,23,24, Michael A Levine25,26, Outi Mäkitie27, Regina Martin28, Gabriel Ángel Martos-Moreno29,30,31, Manasori Minagawa32, Philip Murray33, Arrate Pereda34, Robert Pignolo35, Lars Rejnmark36, Rebeca Rodado11, Anya Rothenbuhler18,37, Vrinda Saraff38, Ashley H Shoemaker39, Eileen M Shore40, Caroline Silve41, Serap Turan42, Philip Woods20, M Carola Zillikens43, Guiomar Perez de Nanclares44, Agnès Linglart17,18,37.
Abstract
Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by physical findings that may include brachydactyly, a short stature, a stocky build, early-onset obesity, ectopic ossifications, and neurodevelopmental deficits, as well as hormonal resistance most prominently to parathyroid hormone (PTH). In addition to these alterations, patients may develop other hormonal resistances, leading to overt or subclinical hypothyroidism, hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable evidence for hormonal abnormalities, type 2 diabetes, and skeletal issues with potentially severe limitation of mobility. PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, radiological, and biochemical presentation, establishment of the molecular diagnosis is of critical importance for patients. It facilitates management, including prevention of complications, screening and treatment of endocrine deficits, supportive measures, and appropriate genetic counselling. Based on the first international consensus statement for these disorders, this article provides an updated and ready-to-use tool to help physicians and patients outlining relevant interventions and their timing. A life-long coordinated and multidisciplinary approach is recommended, starting as far as possible in early infancy and continuing throughout adulthood with an appropriate and timely transition from pediatric to adult care.Entities:
Keywords: Acrodysostosis; Bone disorders; Brachydactyly; Calcium and phosphate metabolism; Consensus; Diagnosis; Management; Ossification; Parathyroid hormone; Pseudohypoparathyroidism; Treatment
Mesh:
Year: 2020 PMID: 32756064 PMCID: PMC8140671 DOI: 10.1159/000508985
Source DB: PubMed Journal: Horm Res Paediatr ISSN: 1663-2818 Impact factor: 2.852